BindRen

RSS
Withdrawn

This medicine's authorisation has been withdrawn

colestilan
MedicineHumanWithdrawn
  • Application under evaluation
  • CHMP opinion
  • European Commission decision

Overview

On 26 March 2015, the European Commission withdrew the marketing authorisation for BindRen (colestilan) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, Mitsubishi Tanabe Pharma Europe Ltd, which notified the European Commission of its decision to permanently discontinue the marketing of the product in the EU for commercial reasons. 

BindRen was granted marketing authorisation in the EU on 21 January 2013 for the treatment of hyperphosphataemia in adult patients with Chronic Kidney Disease (CKD) Stage 5 receiving haemodialysis or peritoneal dialysis. The marketing authorisation was initially valid for a 5-year period. 

The European Public Assessment Report (EPAR) for BindRen is updated accordingly to reflect the fact that the marketing authorisation is no longer valid.

български (BG) (622.19 KB - PDF)

View

español (ES) (541.57 KB - PDF)

View

čeština (CS) (603.24 KB - PDF)

View

dansk (DA) (560.1 KB - PDF)

View

Deutsch (DE) (562.92 KB - PDF)

View

eesti keel (ET) (539.24 KB - PDF)

View

ελληνικά (EL) (650.64 KB - PDF)

View

français (FR) (565.42 KB - PDF)

View

italiano (IT) (540.75 KB - PDF)

View

latviešu valoda (LV) (602.51 KB - PDF)

View

lietuvių kalba (LT) (564.62 KB - PDF)

View

magyar (HU) (599.75 KB - PDF)

View

Malti (MT) (609.45 KB - PDF)

View

Nederlands (NL) (538.37 KB - PDF)

View

polski (PL) (625.17 KB - PDF)

View

português (PT) (539.56 KB - PDF)

View

română (RO) (563.82 KB - PDF)

View

slovenčina (SK) (604.46 KB - PDF)

View

slovenščina (SL) (618.8 KB - PDF)

View

Suomi (FI) (540.67 KB - PDF)

View

svenska (SV) (539.51 KB - PDF)

View

Product information

български (BG) (2.56 MB - PDF)

View

español (ES) (1.17 MB - PDF)

View

čeština (CS) (1.88 MB - PDF)

View

dansk (DA) (1.19 MB - PDF)

View

Deutsch (DE) (1.19 MB - PDF)

View

eesti keel (ET) (1.16 MB - PDF)

View

ελληνικά (EL) (2.43 MB - PDF)

View

français (FR) (1.22 MB - PDF)

View

hrvatski (HR) (1.3 MB - PDF)

View

íslenska (IS) (1.18 MB - PDF)

View

italiano (IT) (1.18 MB - PDF)

View

latviešu valoda (LV) (1.96 MB - PDF)

View

lietuvių kalba (LT) (1.3 MB - PDF)

View

magyar (HU) (1.98 MB - PDF)

View

Malti (MT) (2.07 MB - PDF)

View

Nederlands (NL) (1.19 MB - PDF)

View

norsk (NO) (1.18 MB - PDF)

View

polski (PL) (2 MB - PDF)

View

português (PT) (1.18 MB - PDF)

View

română (RO) (1.35 MB - PDF)

View

slovenčina (SK) (2.04 MB - PDF)

View

slovenščina (SL) (1.93 MB - PDF)

View

Suomi (FI) (1.19 MB - PDF)

View

svenska (SV) (1.16 MB - PDF)

View
Latest procedure affecting product information: IAIN/0004
26/03/2015
icon globe

This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.

 

Product information documents contain:

  • summary of product characteristics (annex I);
  • manufacturing authorisation holder responsible for batch release (annex IIA);
  • conditions of the marketing authorisation (annex IIB);
  • labelling (annex IIIA);
  • package leaflet (annex IIIB).

Product details

Name of medicine
BindRen
Active substance
colestilan
International non-proprietary name (INN) or common name
colestilan
Therapeutic area (MeSH)
Hyperphosphatemia
Anatomical therapeutic chemical (ATC) code
V03AE

Therapeutic indication

Treatment of hyperphosphataemia in adult patients with chronic kidney disease stage 5 receiving haemodialysis or peritoneal dialysis.

Authorisation details

EMA product number
EMEA/H/C/002377
Marketing authorisation holder
Mitsubishi Pharma Europe Ltd

Dashwood House
69 Old Broad Street
London EC2M 1QS
United Kingdom

Marketing authorisation issued
21/01/2013
Withdrawal of marketing authorisation
26/05/2015
Revision
2

Assessment history

This page was last updated on

Share this page